Company: STAA
Filing Date: 2025-11-04
Form Type: DFAN14A
Source: 0001213900-25-106212
Chunk: 2

Company: STAAR SURGICAL CO
Filing Date: 2025-11-04
Form: DFAN14A
Chunk 2
---
IPANTS AND THEIR DIRECT OR INDIRECT INTERESTS, BY SECURITY HOLDINGS OR OTHERWISE. The definitive proxy statement and an accompanying GREENProxy Card will be furnished to some or all of the Company’s stockholders and will be, along with other relevant documents, available at no charge on the SEC’s website at https://www.sec.gov/.

Information about the Participants and a description of their direct or indirect interests, by security holdings or otherwise, is contained on an amendment to Schedule 13D filed by the Participants with the SEC on October 24, 2025 and is available here.

Exhibit 1

<div align='center'>Broadwood Partners Condemns Alcon’s Fallacious Attacks on STAAR Surgical and Its Prospects

Reminds STAAR’s Board That It Does Not Need Alcon’s Permission to Remain Independent or Run a Proper Strategic Alternatives Process</div>

NEW YORK--(BUSINESS WIRE)--Broadwood Partners,
L.P. and its affiliates (“Broadwood” or “we”) today commented on the investor presentation issued by Alcon Inc.
(“Alcon”) (NYSE: ALC) regarding its proposed acquisition of STAAR Surgical Company (“STAAR” or the “Company”)
(NASDAQ: STAA). Broadwood, which owns 27.5% of STAAR’s outstanding common stock, continues to urge its fellow shareholders to vote
on its GREEN Proxy Card “AGAINST” the proposed transaction.

Neal C. Bradsher, Broadwood Founder and President,
said:

“Today’s press release and
presentation from Alcon, which required STAAR’s approval, is disappointingly replete with fallacious arguments and baseless claims,
all in service of preserving Alcon’s privileged but misbegotten position as STAAR’s chosen acquirer. We are dismayed that
the STAAR Board, despite its fiduciary duty to STAAR shareholders, would sanction the publication of such misleading statements regarding
STAAR’s own business prospects and the integrity and results of two of its largest shareholders.

Given the overwhelmingly negative reaction
of STAAR shareholders (and all three proxy advisors) to the timing, process and price of the proposed Alcon transaction, there is no reason
for the Board of Directors to take direction from Alcon. There is no justification for prolonging this process, and the distraction and
damage to STAAR’s business it creates, for Alcon’s benefit. Shareholders should be allowed to reject this transaction, as
they were poised to do before the Board first adj